SCHEMBL91757

SCHEMBL91757

Cc1cc(Cl)c(NC(=O)c2csc3ccccc23)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
RAB9A P51151 4/20 0.52
NPC1 O15118 2/20 0.52
TP53 P04637 2/20 0.52
NFKB1 P19838 2/20 0.52
HTT P42858 2/20 0.52
NFKB2 Q00653 2/20 0.52
RELA Q04206 2/20 0.52
HSD17B10 Q99714 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91650 0.89 SMN1; SMN2 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL92620 0.86 RAB9A (0.46) SMN1; SMN2RAB9ANPC1TP53MAPT
SCHEMBL91763 0.85 RAB9A (0.64) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10285850 0.82 MAOB (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL71893 0.81 HDAC3 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5708317 0.81 SMN1; SMN2 (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL91667 0.80 MAPT (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL91671 0.79 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL24170197 0.78 KCNMA1 (0.61) SMN1; SMN2RAB9ANPC1HTTHSD17B10
SCHEMBL92226 0.78 RAB9A (0.57) HDAC8SMN1; SMN2RAB9ANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 HDAC3 398/4885HDAC4 116/4885HDAC1 222/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 HDAC3 432/4885HDAC4 104/4885HDAC1 208/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 HDAC3 619/4885HDAC4 136/4885HDAC1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.